Key result
Review of apical HCM management notes a prognosis similar to the general HCM population.
Why the study?
Recent studies contradict reports that ApHCM prognosis is relatively benign, showing an adverse event incidence similar to the general HCM population.
This review highlights that apical hypertrophic cardiomyopathy may carry a similar risk of adverse events as general hypertrophic cardiomyopathy, emphasizing the role of cardiac magnetic resonance in its diagnosis.
Apical HCM may warrant similar risk stratification as classic HCM; leaves open need for prospective validation.
Apical hypertrophic cardiomyopathy (ApHCM) represents a rare variant of hypertrophic cardiomyopathy (HCM) with distinct phenotypic characteristics. The prevalence of this variant varies according to each study's geographic region. The leading imaging modality for the diagnosis of ApHCM is echocardiography. Cardiac magnetic resonance, however, is the gold standard for ApHCM diagnosis in case of poor acoustic windows or equivocal echocardiographic findings but also in cases of suspected apical aneurysms. The prognosis of ApHCM was reported to be relatively benign, although more recent studies seem to contradict this, demonstrating similar incidence of adverse events compared with the general HCM population. The aim of this review is to summarize the available evidence for the diagnosis of ApHCM, highlight distinctions in comparison to more frequent forms of HCM with regards to its natural history, prognosis, and management strategies.
No takes yet. Share an insight, caveat, or question.
Rouskas et al. (2023) conducted a review in Apical Hypertrophic Cardiomyopathy. This review summarizes the diagnosis, natural history, and management of apical hypertrophic cardiomyopathy, noting that recent studies suggest a prognosis similar to the general HCM population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: